Substitute	for form 1449A&B/PTO			Complete if Known		
				Application Number	10/817,334	
INFC	RMATION DIS	CLOS	SURE	Filing Date	April 2, 2004	
STATEMENT BY APPLICANT				First Named Inventor	Hammock, Bruce D.	
				Art Unit	1654	
(Use as many sheets as necessary)				Examiner Name	Kosar, Andrew D.	
Sheet	1	of	3	Attorney Docket Number	02307W-131010US	

Examiner	40		U.S. PATENT DO		
Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where
illusia 140.		Number Kind Code ^{2 (Vincen)}	MM-OO-1111	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	C1	US-3,587,060	06-22-1971	Quinn et al.	
	C2	US-3,755,415	08-28-1973	Richter et al.	
	C3	US-5,962,455-A	10-05-1999	Blum et al.	
	C4	US-6,344,358-B1	02-05-2002	Matsuoka et al.	
	C5	US-2002/0090732-A1	07-11-2002	Matsuoka et al.	
	C6	US-6,613,572-B2	09-02-2003	Matsuoka et al.	
	C7	US-2004/0014745-A1	01-22-2004	Yamada et al.	
	C8	US-2004/0054187-A1	03-18-2004	Mammen et al.	
	C9	US-6,710,043-B1	03-23-2004	Yamada et al.	
		US-			

				FOREIGN	PATENT DOCU	JMENTS			
Examiner Initials*	Cite No.1		F	oreign Patent D	ocument	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
madio		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	WINI-DD-11111	Applicant of Cited Document	or Relevant Figures Appear	ľ	
	C10	CA	2 360 360	A1	07-20-2000	Fujisawa Pharmaceutical Co., Ltd.		C	
	C11	EP	0 503 627	A1	09-16-1992	The Green Cross Corporation		Γ	
	C12	EP	1 031 564	A1	08-30-2000	Klinge Pharma GmbH		Ī	
	C13	DD	123 466	A	12-19-1976	Willitzer	Translation of Abstract Only	Σ	
	C14	JP	4-13666	A	01-17-1992	Yamanouchi Pharma Co., Ltd.	Translation of Abstract Only	Σ	
	C15	JP	7-133224	А	05-23-1995	Kyowa Hakko Kogyo KK	Translation of Abstract Only	\boxtimes	
	C16	JP	2001-158789	A	06-12-2001	Nikken Chemicals Co., Ltd.	Translation of Abstract Only	\triangleright	
	C17	JP	2003-522120	Т	07-22-2003	Fujisawa Pharmaceutical Co., Ltd.	Translation of Abstract Only	\boxtimes	
	C18	JP	2004-002414	Α	01-08-2004	Fujisawa Pharmaceutical Co.	Translation of Abstract Only	\triangleright	
	C19	RU	2 208 608	C2	07-20-2003	Fudzisava Farmas Jutikal Ko Lt	Translation of Abstract Only	\triangleright	
	C20	wo	99/07700	A1	02-18-1999	Smithkline Beecham Plc.		Г	

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 809, Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant is on upon collation designation matter (optional). "Applicant is to place a check mark here if English language Translation is attached.

Substitute	for form 1449A&B/	PTO		Complete if Known		
				Application Number	10/817,334	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	April 2, 2004	
				First Named Inventor	Hammock, Bruce D.	
				Art Unit	1654	
(Use as many sheets as necessary)				Examiner Name	Kosar, Andrew D.	
Sheet	2	of	3	Attorney Docket Number	02307W-131010US	

				FOREIGN	PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1		oreign Patent C		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			or Relevant Figures Appear	Ľ
	C21	wo	99/09024	A1	02-25-1999	Smithkline Beecham Plc.	1	ΙC
	C22	wo	00/42011	A1	07-20-2000	Fujisawa Pharmaceutical Co., Ltd.		
	C23	wo	00/48593	A1	08-24-2000	The Regents of the University of California		
	C24	wo	00/72834	A2, A3	12-07-2000	Fujisawa Pharmaceutical Co., Ltd.		
	C25	wo	00/76457	A2, A3	12-21-2000	Smithkline Beecham Corporation		
	C26	wo	01/42212	A1	06-14-2001	Advanced Medicine, Inc.		Г
	C27	wo	02/14311	A2, A3	02-21-2002	Amgen Inc.		Ī
	C28	wo	03/009845	A1	02-06-2003	Schering Corporation		Г
	C29	wo	03/061597	A2, A3	07-31-2003	The Regents of the University of California		
	C30	wo	03/070242	A1	08-28-2003	Celltech R&D Limited		Г
	C31	wo	03/070727	A1	08-28-2003	Amgen Inc.		Г
	C32	wo	03/076426	A2, A3	09-18-2003	Pharmacia & Upjohn Company		
	C33	wo	03/082861	A2, A3	10-09-2003	Glaxo Group Limited		Г
	C34	wo	03/097618	A1	11-27-2003	Glaxo Group Limited		
i	C35	wo	03/097586	A1	11-27-2003	Janssen Pharmaceutica N.V.		
	C36	wo	2004/007459	A2, A3	01-22-2004	Janssen Pharmaceutica N.V.		Ē
·····		_						1

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Induced copy of this form with next communication to applicant.

"Applicant's unique claticur designation number (options)." Applicant is option a check mark here if English language Translation is attached.

Substitute	for form 1449A&B/PTO			Complete if Known		
				Application Number	10/817,334	
INFO	RMATION DI	SCLOS	SURE	Filing Date	April 2, 2004	
STA	TEMENT BY	APPLIC	ANT	First Named Inventor	Hammock, Bruce D.	
				Art Unit	1654	
(Use as many sheets as necessary)				Examiner Name	Kosar, Andrew D.	
Sheet	3	of	3	Attorney Docket Number	02307W-131010US	

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, dity and/or country where published.	T²				
	C37	AN 2000: 473143, CAPLUS abstract of Jefferson et al., "Solid-phase synthesis of a heterocyclic ethylenediamine-derivatized library," J. Comb. Chem., 2(5):441-444 (2000) abstract only					

Examiner	Date
Signature	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with accommunication to applicant.

"Applicant's unjury collation designation number (potional)", Applicant is to place a check mark here if English language Translation is attached.